These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 17567870)
1. Chemoprophylaxis of colorectal cancer in inflammatory bowel disease: current concepts. Levine JS; Burakoff R Inflamm Bowel Dis; 2007 Oct; 13(10):1293-8. PubMed ID: 17567870 [TBL] [Abstract][Full Text] [Related]
2. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Chapman CG; Rubin DT Gastrointest Endosc Clin N Am; 2014 Jul; 24(3):353-65. PubMed ID: 24975527 [TBL] [Abstract][Full Text] [Related]
3. Understanding of chemoprophylaxis and concordance in inflammatory bowel disease. Low A; Love M; Walt R; Kane K; Eksteen B; Goh J World J Gastroenterol; 2010 Feb; 16(5):578-82. PubMed ID: 20128025 [TBL] [Abstract][Full Text] [Related]
4. [Chemoprevention of colorectal cancer in inflammatory bowel disease]. Han SH; Lee J Korean J Gastroenterol; 2014 Jan; 63(1):3-10. PubMed ID: 24463282 [TBL] [Abstract][Full Text] [Related]
5. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046 [TBL] [Abstract][Full Text] [Related]
7. Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment? Sedano Muñoz R; Quera Pino R; Ibáñez Lazo P; Figueroa Corona C; Flores Pérez L Gastroenterol Hepatol; 2019 May; 42(5):339-347. PubMed ID: 30954317 [TBL] [Abstract][Full Text] [Related]
8. Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis. Stokkeland K; Höijer J; Bottai M; Söderberg-Löfdal K; Bergquist A Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1860-1866.e1. PubMed ID: 30448601 [TBL] [Abstract][Full Text] [Related]
9. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Bernstein CN; Eaden J; Steinhart AH; Munkholm P; Gordon PH Inflamm Bowel Dis; 2002 Sep; 8(5):356-61. PubMed ID: 12479651 [TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of colorectal cancer in ulcerative colitis. Croog VJ; Ullman TA; Itzkowitz SH Int J Colorectal Dis; 2003 Sep; 18(5):392-400. PubMed ID: 12904996 [TBL] [Abstract][Full Text] [Related]
11. Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents. Present DH Gastroenterology; 2000 Jul; 119(1):276. PubMed ID: 10928833 [No Abstract] [Full Text] [Related]
12. [Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease]. Gisbert JP; Gomollón F; Maté J; Pajares JM Gastroenterol Hepatol; 2002; 25(6):401-15. PubMed ID: 12069704 [No Abstract] [Full Text] [Related]
13. Role of 5-aminosalicylate in preventing colorectal cancer. Riyaz S; Hamlin J; Everett S Am J Gastroenterol; 2011 Sep; 106(9):1720-1; author reply 1721-2. PubMed ID: 21897414 [No Abstract] [Full Text] [Related]
14. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases]. Ioffe AIu Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715 [TBL] [Abstract][Full Text] [Related]
15. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Tang J; Sharif O; Pai C; Silverman AL Dig Dis Sci; 2010 Jun; 55(6):1696-703. PubMed ID: 19705280 [TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Allgayer H; Kruis W Clin Gastroenterol Hepatol; 2006 Apr; 4(4):521; author reply 521. PubMed ID: 16616360 [No Abstract] [Full Text] [Related]
17. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
18. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
19. [Chemoprevention of colorectal cancer associated with IBD]. Yajima T; Hibi T Nihon Rinsho; 2012 Feb; 70 Suppl 1():390-4. PubMed ID: 23126124 [No Abstract] [Full Text] [Related]
20. [Ulcerative colitis. Cancer prevention]. Schmiegel W; Pox C; Kroesen A Z Gastroenterol; 2004 Sep; 42(9):1014-8. PubMed ID: 15455276 [No Abstract] [Full Text] [Related] [Next] [New Search]